Alex R Menter1, Nikki M Carroll2, Lori C Sakoda3, Thomas Delate4, Mark C Hornbrook5, Rakesh K Jain6, Lawrence H Kushi7, Virginia P Quinn8, Debra P Ritzwoller2. 1. Oncology Department, Kaiser Permanente Colorado, Lone Tree, CO. Electronic address: alex.menter@kp.org. 2. Institute for Health Research, Kaiser Permanente Colorado, Denver, CO. 3. Division of Research, Kaiser Permanente Northern California, Oakland, CA. 4. Pharmacy Department, Kaiser Permanente Colorado, Aurora, CO. 5. The Center for Health Research, Kaiser Permanente Northwest, Portland, OR. 6. Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA. 7. Division of Research, Kaiser Permanente Northern California, Oakland, CA; Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA. 8. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA.
Abstract
INTRODUCTION: Preclinical studies suggest that angiotensin system inhibitors (ASI) and bevacizumab improve tumor perfusion and chemotherapy efficacy. We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, non-small-cell lung cancer (NS-NSCLC). PATIENTS AND METHODS: In a retrospective cohort study, adult patients diagnosed with stage IIIB or IV NS-NSCLC between 2005 and 2011 were identified from tumor registries at 1 of 4 Kaiser Permanente regions. Survival differences between those who did and did not receive ASIs concomitant with chemotherapy (CP or CPB) were assessed using propensity score-matched proportional hazard models. OS was measured from the initiation of chemotherapy until death, disenrollment, or December 31, 2012. RESULTS: Of the 1465 CP and 348 CPB patients included, 273 (19%) and 78 (22%), respectively, received concomitant ASI. For CP patients with and without concomitant ASI exposure, median OS was 12.0 and 8.4 months, respectively (crude hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.63-0.84). For CPB patients, the comparable median OS was 14.9 and 11.9 months, respectively (crude HR, 0.77; 95% CI, 0.57-1.02). Using propensity score-matched cohorts, the HR for concomitant ASI use was 0.73 (95% CI, 0.61-0.88) for CP patients and 0.79 (95% CI, 0.51-1.21) for CPB patients. CONCLUSION: Concomitant ASI receipt during CP or CPB therapy for NS-NSCLC was associated with improved survival, although the association was only statistically significant in the CP group.
INTRODUCTION: Preclinical studies suggest that angiotensin system inhibitors (ASI) and bevacizumab improve tumor perfusion and chemotherapy efficacy. We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, non-small-cell lung cancer (NS-NSCLC). PATIENTS AND METHODS: In a retrospective cohort study, adult patients diagnosed with stage IIIB or IV NS-NSCLC between 2005 and 2011 were identified from tumor registries at 1 of 4 Kaiser Permanente regions. Survival differences between those who did and did not receive ASIs concomitant with chemotherapy (CP or CPB) were assessed using propensity score-matched proportional hazard models. OS was measured from the initiation of chemotherapy until death, disenrollment, or December 31, 2012. RESULTS: Of the 1465 CP and 348 CPBpatients included, 273 (19%) and 78 (22%), respectively, received concomitant ASI. For CP patients with and without concomitant ASI exposure, median OS was 12.0 and 8.4 months, respectively (crude hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.63-0.84). For CPBpatients, the comparable median OS was 14.9 and 11.9 months, respectively (crude HR, 0.77; 95% CI, 0.57-1.02). Using propensity score-matched cohorts, the HR for concomitant ASI use was 0.73 (95% CI, 0.61-0.88) for CP patients and 0.79 (95% CI, 0.51-1.21) for CPBpatients. CONCLUSION: Concomitant ASI receipt during CP or CPB therapy for NS-NSCLC was associated with improved survival, although the association was only statistically significant in the CP group.
Authors: Tobias Kurth; Alexander M Walker; Robert J Glynn; K Arnold Chan; J Michael Gaziano; Klaus Berger; James M Robins Journal: Am J Epidemiol Date: 2005-12-21 Impact factor: 4.897
Authors: Debra P Ritzwoller; Nikki M Carroll; Thomas Delate; Mark C Hornbrook; Lawrence Kushi; Erin J Aiello Bowles; Jared M Freml; Karl Huang; Elizabeth T Loggers Journal: Lung Cancer Date: 2012-09-27 Impact factor: 5.705
Authors: Daniel Keizman; Peng Huang; Mario A Eisenberger; Roberto Pili; Jenny J Kim; Emmanuel S Antonarakis; Hans Hammers; Michael A Carducci Journal: Eur J Cancer Date: 2011-05-18 Impact factor: 9.162
Authors: Eric S Kim; J Jack Lee; Guangan He; Chi-Wan Chow; Junya Fujimoto; Neda Kalhor; Stephen G Swisher; Ignacio I Wistuba; David J Stewart; Zahid H Siddik Journal: J Clin Oncol Date: 2012-08-13 Impact factor: 44.544
Authors: Jenny J Lin; Emily J Gallagher; Keith Sigel; Grace Mhango; Matthew D Galsky; Cardinale B Smith; Derek LeRoith; Juan P Wisnivesky Journal: Am J Respir Crit Care Med Date: 2015-02-15 Impact factor: 21.405
Authors: Y Nakai; H Isayama; H Ijichi; T Sasaki; N Sasahira; K Hirano; H Kogure; K Kawakubo; H Yagioka; Y Yashima; S Mizuno; K Yamamoto; T Arizumi; O Togawa; S Matsubara; T Tsujino; K Tateishi; M Tada; M Omata; K Koike Journal: Br J Cancer Date: 2010-10-26 Impact factor: 7.640
Authors: Suresh S Ramalingam; Suzanne E Dahlberg; Corey J Langer; Robert Gray; Chandra P Belani; Julie R Brahmer; Alan B Sandler; Joan H Schiller; David H Johnson Journal: J Clin Oncol Date: 2008-01-01 Impact factor: 44.544
Authors: Vikash P Chauhan; John D Martin; Hao Liu; Delphine A Lacorre; Saloni R Jain; Sergey V Kozin; Triantafyllos Stylianopoulos; Ahmed S Mousa; Xiaoxing Han; Pichet Adstamongkonkul; Zoran Popović; Peigen Huang; Moungi G Bawendi; Yves Boucher; Rakesh K Jain Journal: Nat Commun Date: 2013 Impact factor: 14.919
Authors: Sergei M Danilov; Roman Metzger; Eckhard Klieser; Karl Sotlar; Ilya N Trakht; Joe G N Garcia Journal: PLoS One Date: 2019-12-26 Impact factor: 3.240
Authors: Daniela Volonte; Morgan Sedorovitz; Victoria E Cespedes; Maria L Beecher; Ferruccio Galbiati Journal: J Biol Chem Date: 2021-01-08 Impact factor: 5.157
Authors: Ruth P Norris; Rosie Dew; Linda Sharp; Alastair Greystoke; Stephen Rice; Kristina Johnell; Adam Todd Journal: BMC Med Date: 2020-10-23 Impact factor: 8.775